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Abstract 
Eosinophilic cellulitis is an uncommon, inflammatory and chronic disorder of unknown etiol-
ogy. Corticosteroids are currently considered as the first-line treatment but they are not 
without significant disadvantages such as contraindications in steroid-resistant cases and 
patients with frequent recurrences. We report a patient suffering from Wells’ syndrome with 
a 24-year history of symptomatic and generalized skin lesions. After consultation in our de-
partment, treatment with colchicine 1 mg/day was prescribed resulting in large clinical im-
provement. No side effects have been recorded. To our knowledge, this is an original disease 
approach. Although small, our clinical experience supports the inclusion of colchicine in the 
drug armamentarium when treating patients suffering from Wells’ syndrome. Indeed, its ex-
cellent safety profile makes it very attractive for patients with frequent recurrent episodes 
who need secure options for the medium- and long-term disease control. 
 © 2017 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Wells’ syndrome is a rare and idiopathic entity whose treatment can be challenging [1, 
2]. We report the case of a woman with bullous eosinophilic cellulitis who was successfully 
treated with colchicine 1 mg/day. 
Case Report 
An otherwise healthy 44-year-old woman presented with a 24-year history of recurrent 
pruritic lesions located on her limbs and face. Skin lesions lasted over 24 h and resolved 
without scarring. No triggers were identified. The patient had been repeatedly treated with 
systemic corticosteroids and antihistamines with bad disease control. Physical examination 
showed erythematous, edematous and blushing plaques partially covered by tense serous 
bullae. Occasionally, edema of lips and eyelids was present (Fig. 1). Laboratory studies 
showed no abnormalities except ANA+ (speckled pattern) and ASMA+ with levels of 1/160 
and 1/80, respectively (normal ranges <1/40). 
There were no findings in radiological images and prick tests were negative to common 
allergens. Direct and indirect immunofluorescences were both negative. Skin biopsies re-
vealed edema in the upper dermis with subepidermal vesicles and a lymphocytic infiltrate 
with degranulated eosinophilic material forming flame figures (Fig. 2, Fig. 3). 
Wells’ syndrome was diagnosed. Colchicine 1 mg/day was prescribed and the lesions 
completely resolved after 4 weeks. Thenceforth, the patient has been treated with colchicine 
1 mg/day for over 24 months. Since the introduction of daily colchicine, an excellent disease 
control has been achieved: recurrences have been very rare, involving a very limited body 
surface area, never developing into vesicles or bullae and healing rapidly. Moreover, no addi-
tional therapies, such as systemic steroids, were needed and no side effects have been rec-
orded. At present, the patient continues with routine outpatient clinical follow-up. 
Discussion 
Eosinophilic cellulitis is an uncommon, inflammatory and recurrent disorder which is 
more frequently observed in adults than in children [3, 4]. Despite its etiology remaining 
unknown, hypersensitive responses to different stimuli such as insect bites, fungal and viral 
infections, medications (including TNF inhibitors), vaccinations, eczema and hematologic 
malignant disorders, among others [3, 4], have been proposed. 
It is clinically characterized by erythematoedematous, painful plaques on the trunk and 
upper limbs that resolve without scarring [5, 6]. These lesions are usually preceded by itch-
ing and evolve developing vesicles or bullae. Wells’ syndrome is often misdiagnosed as bac-
terial cellulitis and should be considered when encountering a case of cellulitis with an atyp-
ical presentation and a lack of response to appropriate antibiotic treatment [1, 6]. 
Diagnosis is based on clinicopathological findings. Histologic features include dermal 
edema, lymphocytic infiltrate with numerous eosinophils, body giant cells and histiocytes 
around collagen fibers [7]. Degranulated eosinophilic material can form flame figures which 
are not pathognomonic and can also be found in insect bites, bullous pemphigoid, eczema, 
and drug reactions, among others [5]. 
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To our knowledge, all treatment options available are related to case reports or to small 
case series. To date, the use of colchicine is only mentioned in one case by Paquet et al. [8], 
who reported on two cases of Wells’ syndrome. Systemic and topical corticosteroids are 
considered as a first-line treatment option, but they are not without well-known significant 
disadvantages in the medium and long term [2]. Although colchicine mechanisms of action 
are still unclear, effects such as inhibition of neutrophil chemotaxis, adhesion, mobilization, 
and superoxide production in addition to inhibition of macrophage inflammasome activation 
have been described. As in other autoinflammatory diseases, colchicine inhibition of micro-
tubule polymerization and altered expression of adhesion molecules and chemotactic factors 
could explain adequate clinical response in our case owing to its anti-inflammatory effect  
[9, 10]. 
In conclusion, we present a patient with Wells’ syndrome successfully treated with col-
chicine 1 mg/day with very good clinical response and no side effects. Despite being limited 
[2, 8], our clinical experience supports colchicine 1 mg/day as an alternative therapeutic 
both on acute onset and as maintenance treatment due to its excellent safety profile. 
Statement of Ethics 
The subject of this case report has given his informed consent. 
Disclosure Statement 
The authors have no conflicts of interest to disclose. 
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Fig. 1. Erythematous, edematous and blushing plaques partially covered by tense serous bullae. 
 
 
 
Fig. 2. Dermal edema with intraepidermal vesicles (asterisk) and a lymphocytic infiltrate with numerous 
eosinophils (white arrows). HE. ×20.  
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Fig. 3. At higher magnification. Degranulated eosinophils forming flame figures (black arrows). HE. ×50. 
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